Applied Genetic Technologies Corporation Receives Grant from FDA for Clinical Study of Genetic Retinal Disease
Published: Sep 14, 2010
GAINESVILLE, Fla.--(BUSINESS WIRE)--Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program). The grant will fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease known to cause blindness at an early age. The clinical trial, coordinated by AGTC, is being conducted at The University of Massachusetts Medical School by Dr. Shalesh Kaushal and Oregon Health & Science University by Dr. Tim Stout.